CKPT News and Press, Checkpoint Therapeutics Inc. From 04/14/24

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Checkpoint To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 14, 2024) - Faruqi & Faruqi, LLP, a leading nation...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Checkpoint To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 11, 2024) - Faruqi & Faruqi, LLP, a leading nation...

2024-03-22 09:05:08 ET More on Checkpoint Therapeutics Checkpoint Therapeutics to raise ~$14M Seeking Alpha’s Quant Rating on Checkpoint Therapeutics Historical earnings data for Checkpoint Therapeutics Financial information for Checkpoint Therapeutics...

WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2023, and recent corporate highlights....

WALTHAM, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the appointment of Amit Sharma, M.D., FACP, FASN, FNKF, to its Board as an independent, non-e...

2024-01-29 08:18:54 ET More on Checkpoint Therapeutics Checkpoint stock plunges 50% on FDA rejection of skin cancer drug Seeking Alpha’s Quant Rating on Checkpoint Therapeutics Historical earnings data for Checkpoint Therapeutics Financial information ...

WALTHAM, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement with a single healthcare-dedicated institution...

WALTHAM, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside cha...

NEW YORK, NY / ACCESSWIRE / December 19, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Checkpoint Therapeutics, Inc. ("Checkpoint" or "the Company") (NASDAQ:CKPT). Investors who purchased Checkpoint securities are encouraged to obtain ...

2023-12-18 10:28:27 ET Shares of Checkpoint Therapeutics ( NASDAQ: CKPT ) plunged 50% in morning trading Monday after the company said the FDA had declined to approve its drug cosibelimab for the treatment of advanced cutaneous squamous cell carcinoma, a common type of skin cancer. ...